|
|
|
| Influence of Pitavastatin Combined With Ticagrelor on Serum Monocyte Chemoattractant Protein 1 and Interleukin 10 Levels in Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention |
| Zhang Wenya |
| Nanyang First People's Hospital,Nanyang 473000,China |
|
|
|
|
Abstract Objective This study was conducted to investigate the effect of pitavastatin combined with ticagrelor on serum monocyte chemoattractant protein 1（MCP-1）and interleukin 10（IL-10）levels in patients with acute myocardial infarction（AMI）after percutaneous coronary intervention（PCI）.Methods 60 patients with AMI who underwent PCI were enrolled in this study and randomly assigned to receive ticagrelor（control group,29 cases）or pitavastatin combined with ticagrelor（observation group,31 cases）.Cardiac function indexes,coagulation states before and after PCI,clinical effects and inflammatory factor levels in the 2 groups were compared.Results Before PCI,no significant differences were found between the 2 groups in left ventricular diastolic function（E/A ratio）and ejection fraction（EF）（P>0.05）.After PCI,the E/A ratio and EF increased significantly in the 2 groups,which were significantly higher in the observation group than in the control group（P<0.05）.Before PCI,no significant differences were found between the 2 groups in fibrin（Fg）and D-dimer（DD）（P>0.05）.After PCI,Fg and D-D decreased significantly in the 2 groups,which were significantly lower in the observation group than in the control group（P<0.05）.The total response rate of the observation group was 93.55%,higher than 72.41% of the control group（P>0.05）.Before PCI,no significant differences were found between the 2 groups in IL-10,MCP-1 and high-sensitivity C-reactive protein（hs-CRP）（P>0.05）.After PCI,levels of IL-10,MCP-1 and hs-CRP in the 2 groups were higher than those before operation.Additionally,the observation group had IL-10 levels but lower MCP-1 and hs-CRP levels than the control group（P<0.05）.Conclusion After PCI,using pitavastatin combined with ticagrelor in the treatment of AMI can effectively help improve cardiac function and curative effect of PCI while reducing the occurrence of inflammatory reactions,increasing IL-10 level and lowering MCP-1 level.
|
|
Received: 18 December 2020
|
|
|
|
|
|
[1] 郑丽梅,张丽敏,张明亮.替格瑞洛对急性心肌梗死PCI术病人血小板功能及微循环血流的影响[J].中西医结合心脑血管病杂志,2020,18(1):121-124.
[2] 胡利群. 个性化护理在急性心肌梗死患者院前急诊护理中的作用[J].心血管康复医学杂志,2018,27(2):213-216.
[3] 彭娜,贺爱珍.溶栓后PCI与直接PCI对急性ST段抬高型心肌梗死的疗效比较[J].浙江医学,2018,40(23):2580-2581.
[4] 丁晨. 瑞舒伐他汀与阿托伐他汀联合替格瑞洛对急性心肌梗死患者PCI后的临床研究[J].中国医药指南, 2019, 17(11):113-114.
[5] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会.急性心肌梗死诊断和治疗指南[J].中华心血管病杂志, 2001, 29(12):710-725.
[6] 李利军, 赵嫦姣.替格瑞洛联合瑞舒伐他汀治疗不稳定型心绞痛的临床疗效观察[J].现代药物与临床, 2015,3(4):399-403.
[7] 雷锐. 不同剂量他汀类药物对早期急性心肌梗死的临床效果和安全性分析[J].中西医结合心脑血管病杂志, 2017, 15(9):1078-1080.
[8] 黄玲芳, 狄宁宁, 周松.替格瑞洛联合匹伐他汀治疗急性心肌梗死临床研究[J].中国药业, 2020, 29(1):83-86.
[9] 谭志晖, 郭瑞威, 谭志胜,等.他汀类药物在治疗急性心肌梗死的临床应用和研究进展[J].中国医药导报, 2018, 15(20):21-24.
[10] 江洋. 瑞舒伐他汀与替格瑞洛联合用药方案治疗非ST段抬高型急性冠脉综合征患者的临床效果及不良反应[J].中国药物经济学, 2020, 15(3):76-78. |
| [1] |
Zhang Wenya. Influence of Pitavastatin Combined With Ticagrelor on Serum Monocyte Chemoattractant Protein 1 and Interleukin 10 Levels in Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention[J]. journal1, 2022, 42(3): 107-108. |
| [2] |
. [J]. journal1, 2022, 42(2): 74-75. |
| [3] |
. [J]. journal1, 2022, 42(2): 67-69. |
| [4] |
. [J]. journal1, 2022, 42(1): 61-62. |
| [5] |
Cao Xianglong. Efficacy of Fasudil Hydrochloride Combined With Aspirin in the Treatment of Acute Myocardial Infarction and Its Influence on Oxidative Stress and Inflammatory Indexes[J]. journal1, 2021, 41(4): 6-7. |
| [6] |
. [J]. journal1, 2021, 41(3): 91-92. |
|
|
|
|
2022, Vol. 42 
